Showing results (251-260 of 367) with videos related to
Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancerKomal Jhaveri, Sherene Loi, Erika Hamilton, et al.Journal of the National Cancer Institute|June 24, 2024
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 studyRebecca Dent, Javier Cortés, Lajos Pusztai, et al.Cell Reports. Medicine|June 7, 2025
Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtypeEun Seop Seo, Sabin Park, Eun Yoon Cho, et al.Investigational New Drugs|July 16, 2021
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumorsBhumsuk Keam, Chan-Young Ock, Tae Min Kim, et al.Oncology|June 7, 2014
Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancersYeon Hee Park, Seock-Ah Im, Eun Yoon Cho, et al.Breast Cancer Research : BCR|January 18, 2024
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancerJieun Park, Eun Sol Chang, Ji-Yeon Kim, et al.Human Genetics|August 26, 2011
The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populationsMyung-Ju Ahn, Hong-Hee Won, Jeeyun Lee, et al.Breast Cancer (Tokyo, Japan)|June 17, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 studyToshinari Yamashita, Joo Hyuk Sohn, Eriko Tokunaga, et al.Cancer Discovery|October 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup AnalysisGuy Jerusalem, Yeon Hee Park, Toshinari Yamashita, et al.Breast Cancer (Tokyo, Japan)|January 23, 2023
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)Shigeru Imoto, Kun Wang, Xi-Wen Bi, et al.Pageof 37